Latest news

• Novavax’s COVID-19 vaccine candidate approved for emergency use by FDA as a booster

  Novavax’s COVID-19 vaccine, Adjuvanted (NVX-CoV2373) has been granted emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) as a booster in adults 18 years and

• US trial data shows Novavax’s COVID-19 vaccine is 90% effective

  New data from a trial conducted in the US and Mexico has showed that Novavax’s COVID-19 vaccine NVX-CoV2373 is 90% effective at preventing COVID-19. ... PREVENT-19 confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile.

• Novavax announces further delays for regulatory filings of COVID-19 vaccine

  Previously, Novavax’s chief executive officer Stanley Erck said that the company was aiming for a US Food and Drug Administration (FDA) emergency approval of its vaccine – NVX-CoV2373 – as early ... Peak capacity for the vaccine is expected in the

• Novavax is close to finalising a COVID-19 vaccine supply deal with the EU

  Earlier this year, reports emerged that Novavax has encountered issues with sourcing some raw materials used in the manufacturing process for NVX-CoV2373. ... The UK government has already signed an advanced purchase agreement with Novavax for 60 million

• GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK

  GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. ... The UK government signed an advanced purchase agreement with Novavax in August 2020 for 60 million doses of